The preliminary responses observed in patients with cholangiocarcinoma harboring FGFR2 fusions and/or mutations, HER2-negative breast cancer including TNBC, and CRPC form the basis for further investigations of tinengotinib. Here, ERBB2 is linked to cholangiocarcinoma.